SGLT2 inhibitor empagliflozin could be a new treatment for children with type 2 diabetes: lancet

Published Date: 04 Mar 2023

United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...

Read Full News

Latest News

Bayer Says FDA Grants Priority Review Designation for Finerenone

Bayer said on Thursday ⁠that the U.S. Food and ⁠Drug Administration had accepted its ⁠supplemental New ‌Drug Application for finerenone and granted priority review...

BioMarin's Drug Shows Significant Growth Gains in Children in Late-stage Trial

BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that ⁠leads to short stature helped boost growth in children, meeting the main goal of a...

Diabetic Peripheral Neuropathy Tied to Dementia Risk in T2D

Diabetic peripheral neuropathy above a certain vibration perception threshold is linked to a notably higher risk for dementia in patients with type 2 diabetes, according to a Danish cohort study.

Finding the Next Weight-Loss Drug in Python Blood

Pythons can go weeks without eating. Now researchers have isolated an appetite-suppressing metabolite in python blood that could spur a new weight-loss therapy.

Diabetes Meds Show Varied Associations With Liver Protection

Different antidiabetic drug classes show distinct associations with the risk for major adverse liver outcomes among patients with type 2 diabetes, according to a network meta-analysis.

Could Digital Obesity Care Help Improve the Economy?

A UK digital obesity programme was associated with > 40% fewer GP visits and markedly lower long-term sick leave within 9 months in a real-world analysis.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Bayer said on Thursday ⁠that the U.S. Food and ⁠Drug Administration had accepted its ⁠supplemental New ‌Drug Application for finerenone and granted priority review...

BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that ⁠leads to short stature helped boost growth in children, meeting the main goal of a...

Diabetic peripheral neuropathy above a certain vibration perception threshold is linked to a notably higher risk for dementia in patients with type 2 diabetes, according to a Danish cohort study.

Pythons can go weeks without eating. Now researchers have isolated an appetite-suppressing metabolite in python blood that could spur a new weight-loss therapy.

Different antidiabetic drug classes show distinct associations with the risk for major adverse liver outcomes among patients with type 2 diabetes, according to a network meta-analysis.

A UK digital obesity programme was associated with > 40% fewer GP visits and markedly lower long-term sick leave within 9 months in a real-world analysis.

News All Time

Acute Kidney Injury Sets Kids Up for Chronic Kidney Disease

A meta-analysis finds increased long-term odds of chronic kidney disease and death in children who survive acute kidney injury.

Cotrimoxazole Tied to More AEs in Older Men With UTIs

The use of cotrimoxazole is linked to about twice the risk of developing adverse events compared with the use of fluoroquinolones among older men with UTIs.

GLP-1 RAs May Independently Boost Testosterone Levels

Increases in testosterone were realized in a large cohort regardless of patient age or BMI at baseline and could not be explained just by weight loss.

New Dosing Option Okayed for X-Linked Hypophosphatemia Drug

The FDA has approved an option to increase the dose and frequency of burosumab-twza for adults whose serum phosphorus remains below normal.

BioMarin's Genetic Disease Therapy Shows Mixed Results in Late-stage Study

BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met ⁠one of the two main goals in a late-stage study.

Many Parents on Obesity Meds Discuss Treatment With Kids

Parents often discuss using obesity medications and related weight or behavior changes with their children.

Menopause Symptoms Worse in Women With Abdominal Obesity

Women with abdominal obesity report a higher burden of certain menopausal symptoms and exhibit a distinct pattern of symptom interrelationships relative to women without abdominal obesity.

Can Lower-Dose Tirzepatide Keep Weight Off?

New trial data suggest some patients may maintain meaningful weight loss after stepping down from the maximum dose of tirzepatide.

Pesticides May Help Explain Rising Early-Onset CRC Rates

A study linked a common herbicide to rising early-onset colorectal cancer, using DNA methylation to trace lifelong exposures rather than relying on patient recall.

Restarting GLP-1s After Stopping: How to Counsel Patients

Many patients taking GLP-1 RAs for weight loss discontinue within the first year. How can clinicians support long-term success with these drugs?

Exclusive-FDA Drug Center Head Expected to Leave After Commissioner's Exit, Sources Say

The acting head of the U.S. Food and Drug Administration's drug center, Tracey Beth Hoeg, is expected to leave the agency just days after Commissioner Marty ⁠Makary...

Implanted Islet Cell Device Could Control Glucose for Weeks

Researchers developed a battery-free device the size of a coin that can deliver islet cells in the body and keep them healthy, no immunosuppression required.

US Cancer Clinics Scramble to Get Experimental Revolution Medicines Pancreatic Cancer Drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await...

Blame for the Obesity Epidemic Falls on Food Industry

The rise of new weight-loss drugs could help reframe obesity as a societal failure driven by the food industry, rather than an individual failing rooted in lack of willpower.

Can GLP-1 Drugs Improve Breast Cancer Survival?

A ‘big’ data study links the diabetes and weight-loss drugs to better long-term survival after breast cancer. Critics are unconvinced.

EyePoint's Late-stage Eye Drug Trials to Continue After Safety Panel Review

EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials ⁠of its experimental eye disease drug Duravyu and recommended the...

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Fear of hair loss might cause some to reject cancer treatment

Telemedicine services linked to reducing excess mortality

How the skin cancer virus outperforms the replication of host cells.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Radiation in Oncology: Advances, Applications, and Accessibility 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

5.

The Growing Challenge of Haematological Malignancies in Older Adults

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot